Treatment of congenital Langerhans cell histiocytosis with cobimetinib.

Benjelloun, Ghita;Roquet-Gravy, Charlotte;Marot, Lilianne;Secco, Léo-Paul;Bulinckx, Audrey;et.al.
(2024) Pediatric Dermatology — Vol. 41, n° 3, p. 515-517 (2024)

Files

PediatricDermatology-2024-Benjelloun-TreatmentofcongenitalLangerhanscellhistiocytosiswithcobimetinib.pdf
  • Open Access
  • Adobe PDF
  • 600.48 KB
Download

Details

Authors
  • Benjelloun, Ghitaorcid-logo
    Author
  • Roquet-Gravy, CharlotteUCLouvain
    Author
  • Marot, LilianneUCLouvain
    Author
  • Secco, Léo-PaulUCLouvain
    Author
  • Baeck, MarieUCLouvain
    Author
  • Bulinckx, Audrey
    Author
Show more
Abstract
We report a case of congenital multisystem Langerhans cell histiocytosis with cutaneous and hematopoietic involvement. After the failure of first-line (vinblastine and prednisolone) and second-line (vincristine and cytarabine) therapies, treatment with cobimetinib, a mitogen-activated protein kinase (MEK) inhibitor, led to the remission of disease and a sustained response after 11 months of ongoing treatment. Protein kinase inhibitors targeting BRAF or MEK could represent a promising future therapeutic option, also in children with LCH.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Benjelloun, G., Roquet-Gravy, C., Marot, L., Secco, L.-P., Roquet-Gravy, P.-P., Baeck, M., & Bulinckx, A. (2024). Treatment of congenital Langerhans cell histiocytosis with cobimetinib. Pediatric Dermatology, 41(3), 515-517. https://doi.org/10.1111/pde.15512 (Original work published 2024)